NCT01500824View on ClinicalTrials.gov

A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 31, 2014

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Crizotinib

Crizotinib, 250 mg BID, will be administered orally at approximately the same time each day on a continuous daily dosing schedule

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01500824 - A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter